Gene News and Research

Latest Gene News and Research

SAFC Pharma expands contract manufacturing services

SAFC Pharma®, a business segment of SAFC®, a member of the Sigma-Aldrich® Group, today announced the completion of an addition to its Carlsbad, Calif., facility that expands the Company's contract manufacturing services for its late phase and commercial clients.

13 Oct 2009

Amsterdam Molecular Therapeutics' AMT-080 granted EMEA Orphan Drug Designation

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, announced today that the European Medicines Agency has granted Orphan Drug Designation to AMT's gene therapy product AMT-080 for the treatment of Duchenne muscular dystrophy.

13 Oct 2009

NIH funds the University of California's consortium for immune disorder research

The University of California, San Francisco has been designated to lead a new consortium that will study a group of severe immune disorders known as primary immunodeficiencies and aims to improve treatment for these often life-threatening diseases. The Primary Immune Deficiency Treatment Consortium comprises 13 centers throughout the United States and has a $6.25 million funding commitment over five years from the National Institutes of Health.

13 Oct 2009

New RNA repair and modification system in bacteria discovered

In new papers appearing this month in Science and the Proceedings of the National Academy of Sciences, University of Illinois biochemistry professor Raven H. Huang and his colleagues describe the first RNA repair system to be discovered in bacteria.

13 Oct 2009

Mechanism by which gene associated with autism and schizophrenia influences behavior identified

A Stanford University School of Medicine researcher has pinpointed the mechanism by which a gene associated with both autism and schizophrenia influences behavior in mice. And just recently, he received a $1.65 million government grant to expand his efforts to include many more such genes.

13 Oct 2009

Orion Genomics enters collaboration and license agreement with Novartis Pharma

Orion Genomics today announced that it has entered into a multi-year collaboration and license agreement with the molecular diagnostics unit of Novartis Pharma AG. Under the collaboration, the parties seek to discover novel epigenetic biomarkers, and both parties have rights to independently develop and commercialize diagnostic products in their respective fields.

12 Oct 2009

BIO disagrees with recommendations of the draft report on Gene Patenting and Licensing

The Biotechnology Industry Organization (BIO) provided comments yesterday to the Secretary’s Advisory Committee on Genetics, Health and Society regarding its draft report on Gene Patenting and Licensing and Their Impact on Patient Access to Genetic Tests. The report makes several recommendations that would restrict the ability to obtain or undermine the enforceability of patents and exclusive licenses with respect to genetic tests.

12 Oct 2009

FDA advisory committee reviews Fibrocell Science's azfibrocel-T for treating wrinkles

Fibrocell Science, Inc. announced today that the U.S. Food and Drug Administration's (FDA) Cellular, Tissue and Gene Therapies Advisory Committee reviewed azfibrocel-T, an autologous cell therapy being investigated for the treatment of moderate to severe nasolabial fold wrinkles in adults.

12 Oct 2009

Findings may reveal new treatments for people suffering from chronic hemoglobin levels

A gene with a significant effect on regulating hemoglobin in the body has been identified as part of a genome-wide association study, which looked at the link between genes and hemoglobin level in 16,000 people.

12 Oct 2009

AACR to host its first Frontiers in Basic Cancer Research Meeting

The American Association for Cancer Research will host its first Frontiers in Basic Cancer Research Meeting in Boston from Oct. 8-11, 2009. The meeting is expected to draw nearly 500 leading scientists to present on high-profile topics like epigenetics, metastasis and systems biology, and create synergies among the many subfields of basic science.

12 Oct 2009

Eric Boerwinkle receives $26 million federal stimulus grant to identify genetic factors influencing common diseases

Eric Boerwinkle, Ph.D., a professor at The University of Texas Health Science Center at Houston, has received a $26 million federal stimulus grant to lead an effort to pinpoint genetic factors affecting the risk of heart, lung and blood diseases.

12 Oct 2009

Women with deleterious gene mutation diagnosed with breast cancer earlier than their previous generation

Women with a deleterious gene mutation are diagnosed with breast cancer six years earlier than relatives of the previous generation who also had the disease and/or ovarian cancer, according to new research from The University of Texas M. D. Anderson Cancer Center.

12 Oct 2009

Riley Hospital for Children commences patient enrollment in clinical trial of cystic fibrosis drug

The Riley Hospital for Children Cystic Fibrosis Center is the first site in the nation to enroll patients ages 6-11 for the first part of a 48-week clinical trial of a promising investigational treatment for cystic fibrosis (CF).

9 Oct 2009

Health Discovery retains Dilenschneider Group to manage its investor and media relations work

Health Discovery Corporation, is pleased to announce that it has retained The Dilenschneider Group, headquartered in New York City, to manage the Company’s investor and media relations work. With offices in New York, Washington, DC and Chicago, the Dilenschneider Group provides its clients with some of the finest and most seasoned communications professionals in the world.

9 Oct 2009

Manual microdissection to remove biopsy cavities from breast cancer specimens essential

Genomic Health, Inc. today announced results from a study demonstrating the critical role of manual microdissection to remove all biopsy cavities from breast cancer specimens. Genomic Health's Oncotype DX is the only commercially available breast cancer test that employs manual microdissection following review by a board certified surgical pathologist with breast expertise to predict a patient's benefit from chemotherapy and risk of disease recurrence.

9 Oct 2009

RXi Pharmaceuticals presents new preclinical data from its advanced RNAi therapeutic platform

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced the presentation of new preclinical data from its advanced RNAi therapeutic platform at its Annual Investor Event held in New York City on Monday, October 5, 2009.

9 Oct 2009

Gene News and Research

Latest Gene News and Research

SAFC Pharma expands contract manufacturing services

Amsterdam Molecular Therapeutics' AMT-080 granted EMEA Orphan Drug Designation

NIH funds the University of California's consortium for immune disorder research

New RNA repair and modification system in bacteria discovered

Mechanism by which gene associated with autism and schizophrenia influences behavior identified

Orion Genomics enters collaboration and license agreement with Novartis Pharma

BIO disagrees with recommendations of the draft report on Gene Patenting and Licensing

FDA advisory committee reviews Fibrocell Science's azfibrocel-T for treating wrinkles

Findings may reveal new treatments for people suffering from chronic hemoglobin levels

AACR to host its first Frontiers in Basic Cancer Research Meeting

Eric Boerwinkle receives $26 million federal stimulus grant to identify genetic factors influencing common diseases

Women with deleterious gene mutation diagnosed with breast cancer earlier than their previous generation

Riley Hospital for Children commences patient enrollment in clinical trial of cystic fibrosis drug

Health Discovery retains Dilenschneider Group to manage its investor and media relations work

Manual microdissection to remove biopsy cavities from breast cancer specimens essential

RXi Pharmaceuticals presents new preclinical data from its advanced RNAi therapeutic platform

New technique developed to assess individual's risk for type 1 diabetes

Gene sequencer donated for cardiovascular research

Transgenomic adds DFCI's Cold-PCR mutation detection technology to its portfolio

New findings on genetic disorder may lead to better treatment of inflammatory bowel disease

eBook: Using iPSCs models for human disease research and drug discovery eBook

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation